The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study
Open accessAbstract
CONTEXT: Whether immunosuppressive treatment adversely affects survival is unclear. OBJECTIVE: To assess whether immunosuppressive drugs increase mortality. DESIGN: Retrospective cohort study evaluating overall and cancer mortality in relation to immunosuppressive drug exposure among patients with ocular inflammatory diseases. Demographic, clinical, and treatment data derived from medical records, and mortality results from United States National Death Index linkage. The cohort's mortality risk was compared with US vital statistics using standardised mortality ratios. Overall and cancer mortality in relation to use or non-use of immunosuppressive drugs within the cohort was studied with survival analysis. SETTING: Five tertiary ocular inflammation clinics. Patients 7957 US residents with non-infectious ocular inflammation, 2340 of whom received immunosuppressive drugs during follow up. Exposures Use of antimetabolites, T cell inhibitors, alkylating agents, and tumour necrosis factor inhibitors. MAIN OUTCOME MEASURES: Overall mortality, cancer mortality. RESULTS: Over 66 802 person years (17 316 after exposure to immunosuppressive drugs), 936 patients died (1.4/100 person years), 230 (24.6%) from cancer. For patients unexposed to immunosuppressive treatment, risks of death overall (standardised mortality ratio 1.02, 95% confidence interval [CI] 0.94 to 1.11) and from cancer (1.10, 0.93 to 1.29) were similar to those of the US population. Patients who used azathioprine, methotrexate, mycophenolate mofetil, ciclosporin, systemic corticosteroids, or dapsone had overall and cancer mortality similar to that of patients who never took immunosuppressive drugs. In patients who used cyclophosphamide, overall mortality was not increased and cancer mortality was non-significantly increased. Tumour necrosis factor inhibitors were associated with increased overall (adjusted hazard ratio [HR] 1.99, 95% CI 1.00 to 3.98) and cancer mortality (adjusted HR 3.83, 1.13 to 13.01). CONCLUSIONS: Most commonly used immunosuppressive drugs do not seem to increase overall or cancer mortality. Our results suggesting that tumour necrosis factor inhibitors might increase mortality are less robust than the other findings; additional evidence is needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Using the National Death Index to obtain underlying cause of death codes.
Sathiakumar, N., Delzell, E., & Abdalla, O. (1998) · Journal of Occupational & Environmental Medicine · doi:10.1097/00043764-199809000-00010 · Cited by 109 · cited 1×
“Causes of death were obtained using the National Death Index “plus” feature, extracted from death certificates in the same manner as for US vital statistics, which has 96% code-recode reproducibility.”
Method
Cited by
Levy-Clarke, G., Jabs, D. A., Read, R. W., Rosenbaum, J. T., Vitale, A., & Van Gelder, R. N. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.09.048 · Cited by 483
Self-citationEuropean Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies
Annese, V., Beaugerie, L., Egan, L., Biancone, L., Bolling, C., Brandts, C., Dierickx, D., Dummer, R., Fiorino, G., Gornet, J. M., et al. (2015) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjv141 · Cited by 428
Mycophenolate Mofetil for Ocular Inflammation
Daniel, E., Thorne, J. E., Newcomb, C. W., Pujari, S. S., Kaçmaz, R. O., Levy-Clarke, G. A., Nussenblatt, R. B., Rosenbaum, J. T., Suhler, E. B., Foster, C. S., et al. (2010) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2009.09.026 · Cited by 257
Self-citationAzathioprine for Ocular Inflammatory Diseases
Pasadhika, S., Kempen, J. H., Newcomb, C. W., Liesegang, T. L., Pujari, S. S., Rosenbaum, J. T., Thorne, J. E., Foster, C. S., Jabs, D. A., Levy-Clarke, G. A., et al. (2009) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2009.05.008 · Cited by 254
Self-citationLlorenç, V., Nakamura, Y., Metea, C., Karstens, L., Molins, B., & Lin, P. (2022) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.63.3.30 · Cited by 20
Metadata
- Authors
- Kempen, J. H., Daniel, E., Dunn, J. P., Foster, C. S., Gangaputra, S., Hanish, A., Helzlsouer, K. J., Jabs, D. A., Kacmaz, R. O., Levy-Clarke, G. A., Liesegang, T. L., Newcomb, C. W., Nussenblatt, R. B., Pujari, S. S., Rosenbaum, J. T., Suhler, E. B., & Thorne, J. E.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2009-07-03
- Volume
- 339
- Issue
- jul03 1
- Pages
- b2480-b2480
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W2027090790
- Cited by
- 185
- References
- 1
- FWCI
- 16.16
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. https://app.cochat.ai/papers/10.1136/bmj.b2480
- The paper
- Kempen, J. H., Daniel, E., Dunn, J. P., Foster, C. S., Gangaputra, S., Hanish, A., Helzlsouer, K. J., Jabs, D. A., Kacmaz, R. O., Levy-Clarke, G. A., Liesegang, T. L., Newcomb, C. W., Nussenblatt, R. B., Pujari, S. S., Rosenbaum, J. T., Suhler, E. B., & Thorne, J. E. (2009). Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ. https://doi.org/10.1136/bmj.b2480
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.